Antibody–drug conjugates for lung cancer in the era of personalized oncology

2019 ◽  
Author(s):  
Biagio Ricciuti ◽  
Giuseppe Lamberti ◽  
Elisa Andrini ◽  
Carlo Genova ◽  
Andrea De Giglio ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Personalized Oncology ◽  
Antibody Drug

scholarly journals Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, and Proteolysis-Targeting Chimeras: The Pharmacology of Cutting-Edge Lung Cancer Therapies

2021 ◽  
pp. e286-e293
Author(s):  
Jennifer W. Carlisle ◽  
R. Donald Harvey
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Kinase Inhibitor ◽  
Small Cell ◽  
Small Cell Lung ◽  
New Agents ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Antibody Drug

The number of therapeutic options available for patients with advanced non–small-cell lung cancer has been led by deeper understanding of molecular drivers, immune function, and fundamental biology. In this article, we describe the relevant clinical pharmacologic characteristics of three broad classes of existing and investigational treatments, with a focus on mechanisms of action, adverse event profiles, pharmacokinetic and pharmacodynamic properties, and known and predicted resistance pathways. Specifically, within the kinase inhibitor class, agents directed against the RET, MET, and KRAS pathways are reviewed. Additionally, the first antibody-drug conjugates that target HER2 and HER3 are in trials and will ideally be available for patients soon. Finally, proteolysis-targeting chimeras approach pathway inhibition through enzyme degradation rather than target inhibition and are a promising platform for new agents in non–small-cell lung cancer and across cancer types. Each of these classes requires knowledge of clinical pharmacologic principles in development and use to ensure patient care in clinics and trials is optimized and personalized, including dosing and scheduling strategies, potential drug interactions, use in special populations, and monitoring parameters. Ideally, oncologists will continue to have new agents available across the non–small-cell lung cancer treatment spectrum to offer to a patient group that, until relatively recently, had few options.

scholarly journals Evaluating 225Ac and 177Lu Radioimmunoconjugates against Antibody–Drug Conjugates for Small-Cell Lung Cancer

2020 ◽  
Vol 17 (11) ◽  
pp. 4270-4279
Author(s):  
Andrew L. Lakes ◽  
Dahlia D. An ◽  
Stacey S. Gauny ◽  
Camille Ansoborlo ◽  
Benjamin H. Liang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Antibody Drug

scholarly journals NRXN1 as a novel potential target of antibody-drug conjugates for small cell lung cancer

Oncotarget ◽  
2020 ◽  
Vol 11 (39) ◽  
pp. 3590-3600
Author(s):  
Takuma Yotsumoto ◽  
Keita Maemura ◽  
Kousuke Watanabe ◽  
Yosuke Amano ◽  
Yoko Matsumoto ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Antibody Drug Conjugates ◽  
Potential Target ◽  
Drug Conjugates ◽  
Antibody Drug

The Rise of the TROP2-Targeting Agents in NSCLC: New Options on the Horizon

Oncology ◽  
2021 ◽  
pp. 1-8
Author(s):  
Yasar Ahmed ◽  
Jose Javier Berenguer-Pina ◽  
Thamir Mahgoub
Keyword(s):  
Lung Cancer ◽  
Treatment Options ◽  
Human Trophoblast ◽  
Antibody Drug Conjugates ◽  
Transmembrane Glycoprotein ◽  
Drug Conjugates ◽  
Therapeutic Development ◽  
Treatment Paradigm ◽  
Epithelial Tumours ◽  
Antibody Drug

<b><i>Background:</i></b> Lung cancer is the most common thoracic malignancy, representing the leading cause of cancer-related deaths worldwide with a 5-year survival rate of &#x3c;10%. <b><i>Summary:</i></b> The emergence of targeted therapy and immunotherapy has changed the treatment paradigm of advanced non-small cell lung cancer (NSCLC). However, for those who are not eligible for such therapy or currently have no available standard treatment options, new precision treatment approaches are needed. Human trophoblast cell-surface antigen 2 (TROP2) is a transmembrane glycoprotein that is highly expressed on several epithelial tumours including NSCLC. TROP2 is recognized as a promising molecular target for therapeutic development in various types of TROP2-expressing malignancies. As a result, several TROP2-targeted therapeutics have recently been developed for clinical use, such as anti-TROP2 antibodies and TROP2-targeted antibody-drug conjugates. <b><i>Key Message:</i></b> This review explores the literature data on the role of TROP2 in cancer development and the potential use of emerging TROP2 antibody-drug conjugates in NSCLC treatment.

Sign in / Sign up

Export Citation Format

Share Document